Skip to main content
Premium Trial:

Request an Annual Quote

Thallion Sells Stake in Caprion for $4.5M

NEW YORK (GenomeWeb News) – Thallion Pharmaceuticals today said that it has sold its remaining stake in Caprion Proteomics for approximately C$4.5 million (US$4.5 million).

The Montreal-based proteomics firm was sold by healthcare investment firm Great Point Partners to an affiliate of Chicago Growth Partners. The sale comes four years after Thallion sold an 80 percent interest in Caprion to Great Point.

Thallion today said that it received approximately C$3.9 million for its remaining stake in Caprion, and it will receive further cash proceeds within the next 15 months of up to C$583,000 which is currently being held in escrow.

Thallion also is entitled to a pro rata share of net proceeds generated from the licensing, selling, or commercialization of diagnostic products or services using certain Caprion products.

Caprion provides biomarker services using its CellCarta and multiplexed multiple reaction monitoring assays as well as diagnostic development services.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.